Publicaciones en colaboración con investigadores/as de Università de Roma La Sapienza (12)

2021

  1. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2014

  1. Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death

    Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180

2011

  1. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial

    British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221

  2. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

    European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384

2009

  1. Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone

    CLINICAL LYMPHOMA & MYELOMA

  2. Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

    CLINICAL LYMPHOMA & MYELOMA

  3. VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

    CLINICAL LYMPHOMA & MYELOMA

  4. VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

    CLINICAL LYMPHOMA & MYELOMA

2008

  1. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

    New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917

  2. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

    Haematologica, Vol. 93, Núm. 3, pp. 431-438

2007

  1. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 357, Núm. 21, pp. 2123-2132

2001

  1. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European group for blood and marrow transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 27, Núm. 5, pp. 511-515